The evolution of biotech from a nascent scientific discipline to a key segment of the new economy
6/26/2000
Robbins-Roth, a regular columnist on the biotechnology industry for Forbes ASAP, traces the evolution of biotech from a nascent scientific discipline to an industry that promises to have an extraordinary impact on our everyday lives. She gets inside the industry, tracking the process from product development, clinical trials and new business models to IPO, including close looks at biotech venture capitalists, financing, mergers, and management practices. The final section of the book explores the investment side of the industry, focusing on the behavior of biotech stocks and the characteristics that make a quality biotech company—one worthy of investment. Robbins-Roth writes with ease about an industry in which she clearly has expertise. From Alchemy to IPO is recommended for its thoroughness and insight into this increasingly important part of the new economy.